Long-Acting Octreotide for the Treatment and Symptomatic Relief of Bowel Obstruction in Advanced Ovarian Cancer

Beattie, 1989, Bowel obstruction in ovarian carcinoma: a retrospective study and review of the literature, J Palliat Care, 3, 275 Tunca, 1981, The management of ovarian-cancer-caused bowel obstruction, Gynecol Oncol, 12, 186, 10.1016/0090-8258(81)90148-7 Baines, 1985, Medical management of intestinal obstruction in patients with advanced malignant disease: a clinical and pathological study, Lancet, 2, 990, 10.1016/S0140-6736(85)90534-3 Dvoretsky, 1988, Distribution of disease at autopsy in 100 women with ovarian cancer, Hum Pathol, 19, 57, 10.1016/S0046-8177(88)80316-2 Feuer, 1999, Systemic review of surgery in malignant bowel obstruction in advanced gynecological and gastrointestinal surgery, Gynecol Oncol, 75, 313, 10.1006/gyno.1999.5594 Jatoi, 2004, Pathophysiology and palliation of inoperable bowel obstruction in patients with ovarian cancer, Support Oncol, 2, 323 Ripamonti, 2001, The role of somatostatin and octreotide in bowel obstruction: pre-clinical and clinical results, Tumori, 87, 1, 10.1177/030089160108700101 Wright, 1971, Water absorption in experimental closed segment obstruction of the ileum in man, Am J Surg, 121, 96, 10.1016/0002-9610(71)90083-3 Shields, 1965, The absorption and secretion of fluid and electrolytes by the obstructed bowel, Br J Surg, 52, 774, 10.1002/bjs.1800521019 Piver, 1982, Survival after ovarian cancer induced intestinal obstruction, Gynecol Oncol, 13, 44, 10.1016/0090-8258(82)90007-5 Castaldo, 1981, Intestinal operations in patients with ovarian cancer, Am J Obstet Gynecol, 139, 80, 10.1016/0002-9378(81)90416-6 Ripamonti, 2002, Palliative management of malignant bowel obstruction, Int J Gynecol Cancer, 12, 135, 10.1046/j.1525-1438.2002.01103.x Mercadante, 2004, Aggressive pharmacological treatment for reversing malignant bowel obstruction, J Pain Symptom Manage, 28, 412, 10.1016/j.jpainsymman.2004.01.007 Tsahalina, 1999, Gastrostomy tubes in patients with recurrent gynecological cancer and intestinal obstruction, BJOG, 106, 964, 10.1111/j.1471-0528.1999.tb08438.x Rubin, 1999, Octreotide acetate long-acting formulation versus open-label subcutaneous octreotide acetate in malignant carcinoid syndrome, J Clin Oncol, 17, 600, 10.1200/JCO.1999.17.2.600 Mangili, 1996, Octreotide in the management of bowel obstruction in terminal ovarian cancer, Gynecol Oncol, 61, 345, 10.1006/gyno.1996.0154 Mercadante, 1994, The role of octreotide in palliative care, J Pain Symptom Manage, 9, 406, 10.1016/0885-3924(94)90178-3 Reichlin, 1983, Medical progress: somatostatin, N Engl J Med, 309, 1495, 10.1056/NEJM198312153092406 Reichlin, 1983, Medical progress (Part 2), N Engl J Med, 309, 1556, 10.1056/NEJM198312223092506 Fallon, 1994, The physiology of somatostatin and its synthetic analogue, octreotide, Eur J Palliat Care, 1, 20 Product insert, LAR octreotide. Scarpignato, 2001, Somatostatin analogs for cancer treatment and diagnosis: an overview, Chemotherapy, 47, 1, 10.1159/000049157 Aaronson, 1993, The European Organization for Research and Treatment of Cancer QLQ-C30: a quality-of-life instrument for use in international clinical trials in oncology, J Natl Cancer Inst, 85, 365, 10.1093/jnci/85.5.365 Cull, 2001, A development of the European Organization for Research and Treatment of Cancer Questionnaire module to assess the quality of life of ovarian cancer patients in clinical trials. A progress report, Eur J Cancer, 37, 47, 10.1016/S0959-8049(00)00369-5 Riley, 1994, Octreotide in terminal bowel obstruction of the gastrointestinal tract, Eur J Palliat Care, 1, 23 Mystakidou, 2002, Comparison of octreotide administration versus conservative treatment in the management of inoperable bowel obstruction in patients with far advanced cancer: a randomized, double-blind, controlled study, Anticancer Res, 22, 1187 Jones, 2004, Octreotide: an active agent in epithelial ovarian carcinoma?, Lancet Oncol, 5, 251, 10.1016/S1470-2045(04)01430-5 Bousquet, 2001, Antiproliferative effect of somatostatin and analogs, Chemotherapy, 47, 30, 10.1159/000049159